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ABSTRACT
Introduction Community- acquired pneumonia (CAP) 
continues to be a major health problem worldwide and 
is one of the main reasons for prescribing antibiotics. 
However, the causative agent is often not identified, 
resulting in antibiotic overtreatment, which is a key driver 
of antimicrobial resistance and adverse events. We aim 
to test the hypothesis that comprehensive molecular 
testing, compared with routine microbiological testing, 
would be effective in reducing antibiotic use in patients 
with CAP.
Methods and analysis We will perform a randomised, 
controlled, open- label clinical trial with two parallel groups 
(1:1) at two tertiary hospitals between 2020 and 2022. 
Non- severely immunosuppressed adults hospitalised 
for CAP will be considered eligible. Patients will be 
randomly assigned to receive either the experimental 
diagnosis (comprehensive molecular testing plus routine 
microbiological testing) or standard diagnosis (only 
microbiological routine testing). The primary endpoint will 
be antibiotic consumption measured as days of antibiotic 
therapy per 1000 patient- days. Secondary endpoints will 
be de- escalation to narrower antibiotic treatment, time 
to switch from intravenous to oral antibiotics, days to 
reaching an aetiological diagnosis, antibiotic- related side 
effects, length of stay, days to clinical stability, intensive 
care unit admission, days of mechanical ventilation, 
hospital readmission up to 30 days after randomisation 
and death from any cause by 48 hours and 30 days after 
randomisation. We will need to include 440 subjects to be 
able to reject the null hypothesis that both groups have 
equal days of antibiotic therapy per 1000 patient- days with 
a probability >0.8.
Ethics and dissemination Ethical approval has been 
obtained from the Ethics Committee of Bellvitge Hospital 
(AC028/19) and from the Spanish Medicines and Medical 
Devices Agency, and it is valid for all participating 
centres under existing Spanish legislation. Results will 
be presented at international meetings and will be made 
available to patients, their caregivers and funders.
Trial registration number ClinicalTrials: NCT04158492. 
EudraCT: 2018-004880-29.
BACKGROUND
Community- acquired pneumonia (CAP) 
is arguably the most important infectious 
disease encountered in clinical practice.1 In 
a recent study conducted in the USA, the 
annual incidence of cases requiring hospi-
talisation was 24.8 per 10 000 adults, with the 
highest rates recorded in the group aged 
65–79 years (63.0 per 10 000 adults) and in 
patients aged ≥80 years (164.3 per 10 000 
adults).2 A review of 98 studies assessing 
the burden of CAP among adults in Europe 
found that its incidence varied by country, 
age and gender3; overall, however, its inci-
dence increases sharply with age.
The prognosis of patients with CAP varies 
greatly. Among those who do not need hospi-
talisation, the mortality rate is below 1%,4 but 
this increases to 4.0%–18% for in- hospital 
and 30- day mortality for hospitalised patients 
and up to 50% for critically ill patients.5 The 
direct and indirect costs of care for patients 
Strengths and limitations of this study
 ► This study will be the first clinical trial to investi-
gate the impact of comprehensive molecular testing 
on antibiotic consumption in community- acquired 
pneumonia (CAP).
 ► The secondary outcomes will allow us to assess the 
impact of this stewardship strategy on the safety of 
the patients admitted with CAP.
 ► Our findings would help physicians to reduce antimi-
crobial use when treating patients with CAP.
 ► The study will be carried out in two centres in the 
same city in Spain which could be a limitation for the 
generalisation of the results.
 ► The molecular testing will not be strictly used as a 
point- of- care diagnostic method.
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with CAP are also very high. Until now, Streptococcus pneu-
moniae remains the main causative pathogen of bacterial 
CAP worldwide.6 Nevertheless, only 38.8%–66.7% of 
CAP episodes achieve microbiological diagnosis using 
conventional techniques.7–9 The growing availability of 
molecular microbiological tests has been associated with 
improved identification of respiratory viruses in observa-
tional studies of CAP.2
In a recent meta- analysis of patients with CAP, 24.5% 
had viral disease and mortality was increased in patients 
with dual bacterial and viral infection.10 Broad- spectrum 
empirical antibiotic coverage in CAP, even in suspected 
viral CAP, is recommended by current guidelines to cover 
the most likely aetiologies at presentation.11 The same 
CAP guidelines encourage attempts to broaden, narrow 
or modify the spectrum of antibiotic therapy based on 
diagnostic test results, but traditional microbiological 
investigations have significant limitations and little influ-
ence on patient management.12–14 Indeed, a randomised 
trial of 177 patients found that the routine implemen-
tation of urine antigen detection tests did not bring 
any substantial disease or economic- related benefits to 
patients hospitalised with CAP.15 Significantly, CAP is one 
of the leading causes of antibiotic prescribing, and often, 
the causative agent is not early identified and patients are 
overtreated. This overuse of antibiotics is a key driver of 
antimicrobial resistance and is known to increase the risk 
of Clostridium difficile infection16 17 and other antibiotic- 
related adverse events.
Importantly, antibacterial resistance has accelerated 
at an alarming rate and has led to a global increase in 
morbidity and mortality.18 19 Antimicrobial stewardship 
is recognised as a key component in the attempts to 
reduce the associated costs and adverse drug events.20 
Stewardship strategies include prospective audit with 
intervention and feedback, clinical pathways, dedicated 
multidisciplinary teams and the use of biomarkers. 
In some studies, antimicrobial stewardship strategies 
have been associated with improvements in antimicro-
bial use for CAP without negatively affecting clinical 
outcomes.21–25
The current empirical approach to CAP management is 
largely driven by the fact that no available tests give results 
fast enough to impact on the decision. It is of special 
concern since it leads to significant overtreatment with 
antibiotics and may also cause adverse outcomes due to 
unexpected pathogens.12 Moving to a pathogen- directed 
approach would therefore help to reduce antibiotic use, 
improve patient outcomes and lead to a major paradigm 
shift in current clinical practice guidelines. The develop-
ment of multiplex real- time PCR assays currently allows 
for the rapid screening of respiratory specimens, such 
as nasopharyngeal swabs, for a wide array of respiratory 
pathogens.24 A recent observational study showed that 
comprehensive molecular testing significantly improved 
pathogen detection in CAP, particularly in antimicrobial- 
exposed patients.25 Interestingly, some authors have eval-
uated the usefulness of comprehensive molecular testing 
as a tool for antimicrobial stewardship, although the 
results have been mixed.26–29
Research question and how the question will be addressed
To date, no randomised trial has evaluated the usefulness 
of rapid and comprehensive molecular testing as an anti-
biotic stewardship strategy for CAP with a safety analysis. 
We therefore want to know, ‘Can comprehensive molec-
ular testing reduce antibiotic use in adult patients hospi-
talised with CAP, without negatively affecting patient 
outcomes?’ To address this question, we will perform a 
randomised, controlled, open- label clinical trial with 
two parallel groups. Patients will be randomly assigned 
to receive comprehensive molecular testing or routine 
microbiological testing (1:1).
DESIGN AND METHODS
Study design and setting
This randomised, controlled, open- label clinical trial 
with two parallel groups will be conducted at two tertiary 
care Spanish hospitals (Bellvitge University Hospital and 
SCIAS- Barcelona Hospital) between 1 March 2020 and 31 
December 2022. It has been registered in the EudraCT 
and ClinicalTrials databases. Current Good Clinical Prac-
tice standards will be followed when performing, moni-
toring, auditing, analysing and reporting the trial. The 
protocol follows the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) initiative’s 
recommendations, and the study results will be presented 
in accordance with the Consolidated Standards of 
Reporting Trials (CONSORT) statement. As required by 
Spanish legislation, the ethical committee of the principal 
investigator’s institution has approved the study, negating 
the need for approval from the ethics committee of the 
other centre.
Patient eligibility and recruitment
All immunocompetent patients aged 18 years or older 
and diagnosed with CAP in the emergency department 
will be screened for study eligibility and recruited consec-
utively in the two participating hospitals (online supple-
mentary file 1). Participants included in the subsequent 
randomisation must meet the inclusion criteria and have 
no reason for exclusion, as indicated below.
Inclusion criteria
 ► Adult patients (18 years of age or older) hospital-
ised with a radiological diagnosis of CAP in the first 
24 hours of the admission giving informed consent.
Exclusion criteria
 ► Pregnancy or nursing women.
 ► Severe immunocompromised patients: chemotherapy 
or radiotherapy in the previous 90 days, use of immu-
nosuppressive drugs, chronic use of corticosteroids 
at a minimum dose of 15 mg/day in the last 2 weeks, 
haematopoietic progenitor transplant, solid organ 
 on F









pen: first published as 10.1136/bm





3Abelenda- Alonso G, et al. BMJ Open 2020;10:e038957. doi:10.1136/bmjopen-2020-038957
Open access
transplant and HIV (patient with a CD4 ≤200 cells/
mm3).
 ► Imminent death (life expectancy ≤24 hours).
 ► Participation in another clinical trial of pharmacolog-
ical treatment.
Randomisation
Randomisation will be performed in computer- generated 
blocks of 10 by a biomedical statistician from the Biosta-
tistics Unit at Biomedical Research Institute of Bellvitge 
(IDIBELL). Randomisation will be 1:1 and stratified by 
hospital site. The random assignment process will be 
centralised electronically through the electronic data 
capture itself. Patients will be enrolled and randomly 
assigned by investigators to receive either the experi-
mental diagnostic approach (comprehensive molecular 
testing plus to routine microbiological testing) or the 
standard diagnostic approach (only microbiological 




The microbiological workup in both study arms will 
include the following procedures. Blood, pleural fluid 
and sputum samples will be cultured in standard media. 
Only good quality sputum samples (<10 squamous cell 
and >25 leucocytes per low- power field (×100) by Gram 
stain) will be processed for culture. Urinary S. pneumo-
niae antigen will be detected by rapid immunochromato-
graphic assay (BinaxNow; Binax), and urinary Legionella 
pneumophila serogroup 1 antigen will be detected by an 
immunoenzymatic method (ELISA (Bartels ELISA); 
Trinity Biotech).
Comprehensive molecular testing in the experimental 
arm will include the point- of- care molecular detection of 
respiratory pathogens (FilmArray Pneumonia Panel Plus, 
BIOFIRE). Semiquantitative detection will be carried out 
in nasopharyngeal or sputum samples, based on avail-
ability from patients, with real- time PCR of 27 microorgan-
isms known to cause pneumonia. Testing will be for the 
following: S. pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, 
Klebsiella pneumoniae, Klebsiella aerogenes, Klebsiella oxytoca, 
Proteus mirabilis, Serratia marcescens, Streptococcus agalactiae, 
Streptococcus pyogenes, Enterobacter cloacae, Escherichia coli 
and Acinetobacter baumannii complex. There will also be 
a qualitative detection of atypical bacteria (ie, L. pneu-
mophila, Mycoplasma pneumoniae and Chlamydia pneumo-
niae) and respiratory viruses (ie, influenza virus subtypes 
A and B, respiratory syncytial virus, parainfluenza virus, 
adenovirus, rhinovirus, human metapneumovirus, boca-
virus, coronavirus, and Middle East respiratory syndrome 
coronavirus).
A major limitation of PCR- based tests is to establish 
whether the detected pathogen is a coloniser. Therefore, 
we will also perform semiquantification of the relative 
bacterial abundance. The microbiological findings will be 
interpreted by an expert microbiologist of the research 
team and considering the isolated microorganism and 
clinical context of each case. This information will be 
provided as soon as possible to the treating physicians 
via the electronic medical record and a telephone 
notification.
Antibiotic therapy and follow-up
Initial empirical antibiotic therapy will be administered 
in the emergency department in accordance with each 
hospital’s guidelines, which recommend using a β-lactam 
agent (eg, ceftriaxone or amoxicillin sodium- clavulanate) 
with or without a macrolide or fluoroquinolone. Combi-
nation therapy is recommended for patients with no 
initial positive microbiological test. Levofloxacin mono-
therapy is indicated for Legionella pneumonia and for 
selected patients, such as those with β-lactam allergy. 
The use of immediate targeted antimicrobial treatment, 
or de- escalation to a narrower spectrum antimicrobial 
regimen, is recommended if a sensitive pathogen is iden-
tified in either study arm.
Attending physicians will determine the duration of 
antimicrobial therapy. Patients will be seen daily during 
their hospital stay by attending physicians and by at least 
one of the investigators. Table 1 describes the procedures 
and visits that will be carried out by the research team.
Primary endpoint
Days of antibiotic therapy (DOT) per 1000 patient- day.30
Secondary endpoints
 ► De- escalation to narrower antibiotic treatment.
 ► Time to switch from intravenous to oral antibiotics.
 ► Days to reach an aetiological diagnosis.
 ► Antibiotic- related side effects (including phlebitis and 
C. difficile infection).
 ► Length of hospital stay.
 ► Days to clinical stability.
 ► Need for admission to an intensive care unit (ICU).
 ► Days of mechanical ventilation.
 ► Need for hospital readmission up to 30 days after 
randomisation.
 ► Death from any cause up to 48 hours after 
randomisation.
 ► Death from any cause up to 30 days after randomisation.
Follow-up and data collection
All patients will be assessed daily by a member of the 
investigating team until discharge or death. A follow- up 
visit will be arranged for all participating patients, 30 days 
after discharge. For patients who do not attend follow- up, 
a structured telephone interview will be used to assess 
outcomes. A summary of the visit schedule and assess-
ments is displayed in table 1.
Researchers will visit emergency department daily 
to stimulate patient recruitment. Baseline data will 
include the following: date and time of randomisation, 
demographic and epidemiological data, antimicrobials 
received in the prior 3 months, antimicrobials given as 
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an outpatient for the current episode, relevant comor-
bidities, clinical features and variables needed for severity 
scores. In addition, the dates and times of diagnostic 
testing and reporting will be collected (ie, for biochem-
ical and microbiological testing), as will those initiating 
empirical and other antimicrobial treatment. We will also 
record any reasons for treatment modification. Adverse 
events related to the study tests and prescribed antibiotics 
will be collected and communicated to the appropriate 
authority. Criteria for discontinuing therapy will include 
patient request and a final diagnosis other than CAP.
All data will be recorded on a secure web applica-
tion used for building and managing online databases 
(REDCap). The sponsor and investigator will have access 
to the final trial dataset. Authorised staff will be free to 
examine the records for quality assurance and audit 
purposes.
Patient and public involvement
This study will not have the participation of patients or 
the public in the design, recruitment or data interpreta-
tion. Nevertheless, the results will be made available to 




We are planning a clinical trial of a discrete response 
variable, DOT, in independent control and experimental 
subjects (1:1). A previous observational study25 reported 
detection rates of 87% using comprehensive molecular 
testing and 55% using ‘standard care’. When the aeti-
ology is known, the expected DOT is 8 days, increasing to 
11 days when it is unknown. Response within each subject 
group is non- normally distributed. If the true difference 
in the experimental and control means is 2 DOTs, we will 
need to study 220 experimental subjects and 220 control 
subjects to be able to reject the null hypothesis with a 
probability above 0.8. The type I error probability associ-
ated with this test of the null hypothesis is 0.05, assuming 
an expected dropout rate of 10%.
Type of analysis
Efficacy analysis
The baseline characteristics of participants allocated to 
each study group will be described in tables, using statis-
tics that depend on the data distribution will describe. The 
primary and secondary endpoints will then be assessed.
Table 1 The procedures that will be carried out at each visit from baseline to the end of the study
Day
Baseline During admission Discharge Study end
Day 0; inclusion, 
allocation and 
treatment start
Days +1, +2, +n
(throughout admission) Day of discharge
30±5 days after 
discharge
Inclusion exclusion criteria ✓       
Informed consent ✓       
Randomisation ✓       
Demographic data ✓       
Vital signs (BP, HR, RR, SO2, T°C) ✓ ✓ ✓ ✓
Physical examination ✓ ✓ ✓ ✓
Blood analysis: CBC, electrolytes, renal 
function, hepatic tests, coagulation tests
✓†     ✓
Arterial blood gas analysis ✓‡       
’Standard diagnosis’* ✓ ✓§ ✓§ ✓§
‘Standard diagnosis’+‘Multiplex PCR’
Atypical pneumonia serology ✓     ✓
Clinical stability   ✓ ✓ ✓
Chest X- ray ✓     ✓
Antimicrobial therapy ✓ ✓¶ ✓¶ ✓¶
SAE registry ✓ ✓ ✓ ✓
Concomitant medications registry ✓ ✓ ✓ ✓
*Standard diagnosis comprised blood culture, sputum culture, urinary antigen test and other cultures at the treating physician’s discretion.
†Includes the determination of C reactive protein.
‡Indicated when respiratory insufficiency present.
§The results of the microbiological tests will be updated daily.
¶All changes in antimicrobial treatment made by treating physicians and the reason for such changes will be collected daily.
BP, blood pressure; CBC, complete blood count; HR, heart rate; RR, respiratory rate; SAE, serious adverse event; SO2, oxygen saturation; T°C, body 
temperature in degree Celsius.
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For the primary endpoint, the DOT per 1000 patient- 
days will be estimated by study group and compared 
using the Wilcoxon rank- sum test. The probability that an 
individual from the experimental group presents a lower 
DOT value than the control group will also be reported.
For the secondary endpoints, Poisson regression model-
ling will be used to compare the DOT per 1000 patient- 
days by study group adjusted for age, sex, Charlson 
Comorbidity Index (CCI) and Pneumonia Severity Index 
(PSI). The percentages of participants undergoing de- es-
calation, presenting with antibiotic- related side effects or 
needing ICU admission will be reported by study group and 
compared using the χ2 test. Logistic regression modelling 
will be used to assess de- escalation and antibiotic- related 
side effects by study group, making adjustments for age, 
sex, CCI and PSI. Time to switch from intravenous to oral 
antibiotics, days to reach an etiological diagnosis, length 
of hospital stay, days to clinical stability, days to de- escala-
tion and days admitted to ICU will be reported by study 
group and compared using the Wilcoxon rank- sum test. 
Poisson regression modelling will be used to compare 
length of hospital stay by study group and compared 
using the χ2 test. Survival time in the study groups will be 
analysed by Cox proportional hazards models, adjusting 
for the factors mentioned above.
All analyses will be performed according to the 
intention- to- treat principle. We will also conduct a sensi-
tivity analysis in the per- protocol dataset. Statistical signif-
icance will be considered where the p value is ≤0.05. Data 
management and statistical analysis will be performed 
using statistical package R, V.3.4.3 or greater.
Interim analysis
To ensure sufficient statistical power, the sample size 
will be recalculated once half of the initial study popula-
tion (220 patients) has been recruited. The necessity to 
increase the initial estimated sample size will be consid-
ered based on any encountered variabilities. All data 
will be monitored by the Data Monitoring Committee 
of IDIBELL Clinical Research and Clinical Trials Unit, 
which is cofunded by the European Union and the 
Instituto de Salud Carlos III and is independent of the 
sponsor.
Adverse events reporting
An independent safety monitoring committee will review 
safety data regarding antimicrobial treatment and inci-
dents regarding comprehensive multiplex PCR, as local 
legislation requires. All severe adverse events, including 
related adverse events and death, will be recorded on the 
electronic case report form according to the Common 
Terminology Criteria for Adverse Events. The investiga-
tors will declare any serious adverse events to the sponsor 
within 24 hours, and we will present a yearly security 
update report to the local regulatory agency, consistent 
with the recommendations of the International Council 
for Harmonisation.
Indemnities
This study is classified as a low- intervention trial. According 
to Spanish legislation (Real Decreto 1090/2015), all 
damages incurred should be covered by the civil liability 
insurance of the participating study centres. An ad hoc 
insurance for the SCIAS- Hospital of Barcelona (private 
institution) has been taken out.
Trial status
Recruitment started on 24 February 2020 and trial 
enrolment is planned to run from February 2020 to 
December 2022. The present manuscript describes 
the protocol authorised at submission: version 3.0; 8 
October 2019.
Protocol amendments
Any protocol modifications will not become effective 
until approved by relevant authorities and by the Drug 
Research Ethics Committee (CEIm). Exceptions are 
changes to protect patients from imminent harm and 
those concerning exclusively logistic or administrative 
aspects.
A protocol amendment adding pneumonia caused by 
SARS- CoV-2 to the exclusion criteria has been submitted 
and is currently pending decision from the relevant 
authorities and the Drug Research Ethics Committee.
ETHICS AND DISSEMINATION
Ethical approval was obtained by the Clinical Research 
Ethics Committee of Bellvitge (reference number HUB- 
INF- RADICAP; AC028/19) and the Spanish Medicines 
and Medical Devices Agency (AEMPS) and is valid for 
all participating centres that were located within the 
same autonomous community. This study did not have 
the participation of patients or the public in its design. 
Informed consent will be obtained from all patients or 
their relatives by the principal investigators. The study 
will be carried out in accordance with current Spanish 
(Real Decreto 1090/2015) and European (Regulation 
536/2014) legislation, and it will follow the principles of 
the Declaration of Helsinki (ISO 14155:2011).
We will communicate preliminary results to interna-
tional and national infectious disease congresses and will 
publish a manuscript with the final study results in an 
appropriate peer- reviewed journal. Any formal presenta-
tion or publication of data collected from this study will 
be considered as a joint publication by the participating 
investigators and will follow the recommendations of 
the International Committee of Medical Journal Editors 
(ICMJE). Furthermore, the results of this will be made 
available to patients, caregivers and funders. Individual 
participant data that underlie the results of the study will 
be available on request after deidentification. To gain 
access, data requestors will need to sign a data access 
agreement.
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DISCUSSION
Although a large number of causative pathogens are 
associated with CAP, the aetiology remains unknown 
in around 40%–50% of cases.1 In addition, antimicro-
bial resistance is a critical public health issue that has 
led to the need for antimicrobial stewardship strategies 
worldwide. When managing CAP, these strategies seek to 
promote antimicrobial de- escalation, to reduce the treat-
ment duration and to ensure switching to oral treatment 
whenever possible.
Some studies have shown that comprehensive molec-
ular testing could reduce antibiotic use in CAP, although 
with some drawbacks. For example, Gelfer et al conducted 
a non- blinded cluster randomisation trial of 59 patients 
with viral CAP and showed that the use of multiplex PCR 
could reduce duration (days) of antimicrobial therapy 
(p=0.003).26 However, no safety analysis was performed 
to check outcomes and the authors found no differ-
ences between patients with only bacterial CAP and those 
coinfected with both viral and bacterial CAP. In a larger 
quasi- randomised study of 545 patients with lower respi-
ratory tract infection, Andrews et al showed that there 
was no association between multiplex PCR use and either 
reduced antimicrobial treatment or reduced hospital 
stays.31 Nevertheless, this work was limited by using a 
heterogeneous sample of patients with lower respiratory 
tract infection and by failing to conduct a safety analysis. 
Furthermore, in a recent randomised controlled study 
of 800 patients with lower respiratory tract infection,29 
researchers found that multiplex PCR use was associated 
with a reduced duration of intravenous antibiotic use, a 
shorter length of hospital stay and lower costs of hospi-
talisation. Major limitations of this study were that it was 
a single centre study, and as with the other studies,26 29 31 
it failed to include a safety analysis. As suggested by Vos 
and Oosterheert,32 safety analysis is critical when we seek 
to assess the real outcomes and costs associated with the 
implementation of new diagnostic methods for antimi-
crobial stewardship.
We hypothesise that adding comprehensive molecular 
tests to the routine microbiological diagnostic process 
could help to reduce antibiotic consumption without 
negatively affecting morbidity and mortality. Indeed, it 
may even help to reduce the negative effects associated 
with antimicrobial therapy, such as phlebitis and C. diffi-
cile infection. Only by including a safety analysis can we 
assess these aspects. This randomised controlled trial is 
designed to test this hypothesis, and we anticipate that the 
results will uncover the real- world clinical impact of this 
techniques because the research team will not interfere 
with decisions about treatment adjustment. Even nega-
tive results will add to our knowledge about the role of 
this technique in clinical settings, specifically regarding 
any safety issues that arise from its implementation in 
usual clinical practice. In conclusion, we expect that our 
findings will help doctors to improve antimicrobial stew-
ardship by safely reducing the use of broad- spectrum anti-
microbials in patients with CAP.
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